Search

Ferrous ascorbate

Emapalumab

Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. … Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.

Vardenafil

of cGMP in the smooth muscle cells of the corpus cavernosum. … [A258318] The FDA approved the use of vardenafil for the treatment of erectile dysfunction in 2003.

Chlorzoxazone

It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)

Cenegermin

It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. … Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli.

Oliceridine

Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors. … [A218026, A218031, A218051, A218056, A218061, A218066, A218071, L15516] Oliceridine was first reported in 2013,[A218026, A218086] but was initially not approved by the FDA due to concerns raised by

Aminopterin

In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis. … Aminopterin is an amino derivative of folic acid, which was once used as an antineoplastic agent in the treatment of pediatric leukemia.

Deutetrabenazine

In clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo [A32046]. … It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets.

Asenapine

It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009. … Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with

Talimogene laherparepvec

Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. … It specifically replicates within tumor cells and causes lysis. It was approved by the FDA in 2015 under the market name Imlygic.